ICAN®—International Cancer Advocacy Network
ICAN Co-authors Letter on COVID-19 Intellectual Property Waiver
"Waiving intellectual property rights on COVID-19 vaccines initially sounds good, but is a threat to the drug discovery pipeline that cancer patients and all patients depend on."
— Marcia K. Horn, ICAN CEO and Exon 20 Group Executive Director Read the letter
ICAN® is a 501(c)(3) patient advocacy and
research advocacy organization
with a small staff of professional advocates assisted by hundreds
volunteers worldwide. With our volunteer leadership representing
17 different time zones, we literally work around the clock,
focusing on our Personalized Medicine Cancer Case Navigation
Programs, health information technology issues, legislative
initiatives, and research projects.
We aim to provide you with the best patient advocates and the most effective cancer patient advocacy possible, with the twin goals of working to extend your life with
the highest quality of life.
ICAN® advocates for you – the patient – or for the patient's spouse or family member who wants to manage the details of their loved one's cancer case with us.
We are beholden to no one – no oncology practice,
no medical center, no clinical trial, and no biotech or
Your case is unique and in our many years of
non-stop advocacy services, we've never seen two patient cases
ICAN® empowers you to navigate rapidly-expanding
diagnostic and personalized treatment options. This information will assist you in informed discussions with
family and providers.
We never, ever, compromise patient privacy (zealous implementers of HIPAA) – We will not disclose your name or any identifying information, or exploit your case for fundraising purposes.
Know Your Precise Cancer Diagnosis
If your oncologist cannot tell you what molecular subtype of cancer you have, then you may not have a specific diagnosis yet. And your surgical or biopsy tissue might not have been adequately profiled if your physician did not order comprehensive biomarker testing. Here's a pie chart, created by the brilliant Jacqulyne ("Jackie") Robichaux, PhD, member of the John V. Heymach, MD, PhD Laboratory and Assistant Professor at The University of Texas MD Anderson Cancer Center, which reveals the molecular subtypes of Non-Small Cell Lung Cancer. If you know your particular molecular subtype, treatment decisions will likely be more targeted. If comprehensive biomarker testing does not reveal a specific molecular subtype, then that's also important information for you and your oncologist to have.Expand Chart InfoGraphic or select (PPTX) (Text Only) (JPG)
Visit ICAN's special advocacy initiative and global coalition of 1000+ patients, care partners, oncologists, molecular profiling labs, and industry partners:
Working toward turning the rare diagnoses EGFR exon 20 insertions and HER2 exon 20 insertions--each found in 25 separate cancers--into chronic and maintenance diseases.
Federal Tax I.D.: EIN 86-0818253
This website provides information about ICAN® Personalized Medicine Cancer Case Navigation Programs, while it also describes the ICAN® multi-faceted mission, unique vision, and respected values. Intended for use by the general public. This site also offers more in-depth information for target populations who may benefit from ICAN® Program Services such as ICAN® patients, their caregivers and medical teams — along with those healthcare professionals and researchers who are involved with ICAN® medical and scientific councils.
The health news displayed on this site are chosen by our team of M.D.s, PhDs, and ICAN® President and CEO, who is an Affiliate Member of ASCO, the American Society of Clinical Oncology; AMP, the Association for Molecular Pathology; and AACR, the American Association for Cancer Research. Information contained herein is therefore not intended to substitute for or supersede any advice that a patient receives from his/her health professional and is not intended to compromise in any way the patient-physician relationship. ICAN® strongly believes that all medical decisions need to be made, via shared decision-making, by the patient and his/her medical team.